Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health reported second quarter 2021 results with Mytesi net revenue of approximately $0.4 million, marking an 88% decline from $3.2 million in Q2 2020. Gross revenue for Mytesi fell 22% to $4.9 million compared to $6.3 million in the same quarter last year. The company is shifting to direct sales through specialty pharmacies, which aims to lower distribution costs and enhance patient access. Increased R&D expenses of $3.9 million illustrate ongoing clinical trial commitments. The net loss for the quarter was $14.1 million, worsening from $9.2 million in Q2 2020.
Jaguar Health (NASDAQ:JAGX) has announced a time change for its upcoming investor webcast on August 13, 2021, now scheduled for 8:00 AM Eastern Time.
The company focuses on developing plant-based medications aimed at treating gastrointestinal issues, particularly chronic diarrhea in patients with HIV/AIDS. Their product, Mytesi, is FDA approved for this purpose.
Jaguar will file its Q2 2021 10-Q on the same day as the webcast.
Jaguar Health (NASDAQ:JAGX) announced an investor webcast scheduled for August 13, 2021, at 8:30 AM ET to discuss Q2 financials and company updates. Additionally, in recognition of African Traditional Medicine Day on August 31st, Jaguar is launching an educational awareness contest to honor Indigenous healers. Participants can enter the contest for free, with entries due by 9:00 AM ET on August 31, 2021. The winner will receive a signed painting by Anthony J. Conte. For more details, visit Jaguar's official website.
Jaguar Health (NASDAQ:JAGX) announced the adjournment of its Annual Meeting of Stockholders to September 3, 2021, due to insufficient quorum. Over 75% of votes cast supported proposals 2, 3, 4, and 6. Only an additional 0.84% of eligible stock needs to vote for quorum to be achieved. The company emphasized the importance of shareholder participation, which has been costly and distracting. Stockholders can vote online or through their brokers. No changes were made to the proposals, and the record date remains April 12, 2021.
Jaguar Health (NASDAQ:JAGX) announced an upcoming investor webcast featuring CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The event aims to provide updates on Jaguar and its subsidiaries, including Napo Pharmaceuticals and Napo EU S.p.A. The recent financing closure by Dragon SPAC for approximately €8.83 million underscores Jaguar's focus on expanding its plant-based gastrointestinal medicines. The company’s Mytesi product, approved by the U.S. FDA, offers symptomatic relief for adults with HIV/AIDS experiencing noninfectious diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announces an upcoming investor webcast featuring an interview with CEO Lisa Conte on July 29, 2021, at 8:30 AM ET. The session will cover business updates for Jaguar and its subsidiaries, including Napo Pharmaceuticals. Recently, Dragon SPAC S.p.A. completed financing for approximately €8.83 million. Jaguar focuses on developing non-opioid, plant-based medicines for gastrointestinal issues. The FDA-approved product Mytesi® provides symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health (NASDAQ:JAGX) announced the grant of nonstatutory stock options and restricted stock units (RSUs) to two new employees effective July 15, 2021. Each employee received options for up to 8,000 shares at an exercise price of $1.41 per share, vested over three years. Additionally, 4,000 RSUs were granted to each employee, vesting equally over the same period. These grants were approved by the Compensation Committee as an inducement for employment, contingent on continued service with the company.
Napo EU, a target of Dragon SPAC, aims to develop crofelemer to treat short bowel syndrome (SBS), having received orphan-drug designation from the US FDA. The merger of Napo EU and Dragon SPAC is anticipated to finalize within 80 days, with potential license and milestone fees up to $12.5 million. Recent financing closed with €8.83 million (approx. $10.8 million) from Jaguar Health, Inc. (NASDAQ:JAGX). The global SBS market is projected to grow from $568 million in 2019 to $4.6 billion by 2027.
Jaguar Health (NASDAQ:JAGX) announced the completion of the Phase 2 HALT-D study, investigating Mytesi® (crofelemer) for diarrhea relief in HER2 positive breast cancer patients undergoing chemotherapy. Sponsored by Georgetown University and funded by Genentech, results have been submitted for presentation at the San Antonio Breast Cancer Symposium in December 2021. The study aims to address common chemotherapy-related diarrhea, which can hinder treatment adherence and patient outcomes. Jaguar looks forward to potential publication of these results, separate from the ongoing Phase 3 trial of crofelemer.
Jaguar Health, Inc. (NASDAQ:JAGX) has adjourned its Annual Meeting of Stockholders for the third time due to insufficient quorum. Over 74% of votes cast favor Proposals 2, 3, 4, and 6. The meeting will reconvene on August 6, 2021, at 8:30 AM PST to encourage more participation. As of April 12, 2021, stockholders are reminded to vote if they haven't done so. The company emphasizes that approximately 2.9% of eligible stock must vote to reach quorum. The proposals remain unchanged, and voting options are provided for stockholders.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
